Lansoprazole Tablet, Orally Disintegrating
FDA Label NDC 70771-1132

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Lansoprazole (NDC 70771-1132). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

NDC 70771-1132-4

Lansoprazole Delayed-release Orally Disintegrating Tablets, 15 mg

Rx only

100 Tablets (10 x 10 Unit Dose)

Lansoprazole Delayed-release Orally Disintegrating Tablets, 15 mg (Eccba344 1050 416e B6bc 12d9081562d0 04)

Lansoprazole Delayed-release Orally Disintegrating Tablets, 15 mg (Eccba344 1050 416e B6bc 12d9081562d0 04)

NDC 70771-1133-4

Lansoprazole Delayed-release Orally Disintegrating Tablets, 30 mg

Rx only

100 Tablets (10 x 10 Unit Dose)

Lansoprazole Delayed-release Orally Disintegrating Tablets, 30 mg (Eccba344 1050 416e B6bc 12d9081562d0 05)

Lansoprazole Delayed-release Orally Disintegrating Tablets, 30 mg (Eccba344 1050 416e B6bc 12d9081562d0 05)

* Please review the disclaimer below.